Business
Jenex Finalizing Protocol to Test TherOZap(TM) Against the Zika Virus with University Health Network
Toronto, Ontario--(Newsfile Corp. - May 23, 2017) - The Jenex Corporation (TSXV: JEN.H) ("Jene...
About this update from Therma Bright Inc.
[{"type":"text","content":"Jenex Finalizing Protocol to Test TherOZap(TM) Against the Zika Virus with University Health NetworkToronto, Ontario--(Newsfile Corp. - May 23, 2017) - The Jenex Corporation (TSXV: JEN.H) (\"Jenex\" or the \"Company\"), a progressive medical device technology company, is pleased to report that after extensive collaboration with Techna Institute and University Health Network (\"UHN\"), the Company is now in the final stages of designing a testing protocol for the patent pending TherOZap™ device to determine its effectiveness at inactivating the Zika virus. Through this collaboration Jenex and UHN have agreed to start the initial testing of the TherOZap™ device to focus on the Zika virus and provided Jenex receives successful results, further tests will include the West Nile virus and potentially other mosquito-borne diseases. The estimated timeline to begin the tests will be during mid-to-late June with results of the tests expected by late August. Jenex expects to report back as the testing progresses, including any changes to timing. It is anticipated that once all testing is complete, Jenex will finalize the features for the consumer product device and seek regulatory approval where required. Rob Fia, CEO commented:\"Through our collaboration with UHN, we've learned a lot about the Zika virus and other mosquito borne diseases and the potential impact that our TherOZap™ device could have against the Zika virus. We are pleased about the future for our TherOZap™ device as this could very well be the stepping stone to test the device against other well known mosquito borne diseases and to potentially use the TherOZap™ device for other applications. Jenex is excited to begin initial testing and looks forward to working with UHN to determine the effectiveness of the device at inactivating the Zika virus.\"Jenex received a Class II medical device status from the FDA for its platform technology that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites, (including bees, wasps, hornets, mosquitoes, black flies and jellyfish). Jenex received approval for the above claims from FDA (United States) in 1997. Jenex continues to further develop, and explore other applications, for its platform technology.About Jenex:Jenex is a p...